Market Place
Sourcing Support
Lilly Completes $3.2B Acquisition of Morphic
19 Aug 2024 //
CONTRACT PHARMA
Lilly Completes Acquisition Of Morphic To Expand IBD Treatment Options
16 Aug 2024 //
PR NEWSWIRE
Eli Lilly to acquire Morphic for $3.2 billion
08 Jul 2024 //
PRESS RELEASE
Morphic to Participate in Jefferies Global Healthcare Conference
31 May 2024 //
GLOBENEWSWIRE
Morphic Shows Real-Time Small Molecule Gut Cell Trafficking Inhibition
21 May 2024 //
GLOBENEWSWIRE
Morphic to Participate in RBC Capital Markets Global Healthcare Conference
09 May 2024 //
GLOBENEWSWIRE
Morphic Announces Corporate Highlights And Financial Results For Q1 2024
25 Apr 2024 //
GLOBENEWSWIRE
Morphic Appoints Dr. Simon Cooper as Chief Medical Officer
19 Mar 2024 //
GLOBENEWSWIRE
Morphic Therapeutic Taps Simon Cooper as Chief Medical Officer
19 Mar 2024 //
CONTRACT PHARMA
Morphic to Participate in March Investor Conferences
05 Mar 2024 //
GLOBENEWSWIRE
Morphic Announces Financial Results for the Full Year 2023
22 Feb 2024 //
GLOBENEWSWIRE
Morphic to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Morphic to Present at November Investor Conferences
10 Nov 2023 //
GLOBENEWSWIRE
Morphic Announces Financial Results for the Third Quarter 2023
03 Nov 2023 //
GLOBENEWSWIRE
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
09 Oct 2023 //
GLOBENEWSWIRE
Morphic Announces CEO Dr. Praveen Tipirneni to Take Temporary Medical Leave
26 Sep 2023 //
GLOBENEWSWIRE
Morphic`s stock sinks as data on oral Entyvio rival disappoint
25 Sep 2023 //
FIERCE BIOTECH
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057
22 Sep 2023 //
GLOBENEWSWIRE
Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
29 Aug 2023 //
GLOBENEWSWIRE
Morphic to Present at the Canaccord Genuity 43rd Annual Growth Conference
09 Aug 2023 //
GLOBENEWSWIRE
Morphic Announces Financial Results for the Second Quarter 2023
03 Aug 2023 //
GLOBENEWSWIRE
Morphic to Present at the Jefferies Global Healthcare Conference
06 Jun 2023 //
GLOBENEWSWIRE
Morphic to Present at 2023 RBC Capital Markets Global Healthcare Conference
12 May 2023 //
GLOBENEWSWIRE
Morphic Presents Biomarker Data at DDW 2023 Supporting MORF-057 Program
11 May 2023 //
GLOBENEWSWIRE
Morphic Therapeutic Announces Closing of Public Offering & Full Exercise
05 May 2023 //
GLOBENEWSWIRE
Morphic Therapeutic Announces Pricing of $240.0 Million Public Offering
03 May 2023 //
GLOBENEWSWIRE
Morphic Therapeutic Announces Proposed Public Offering
02 May 2023 //
GLOBENEWSWIRE
Morphic shares swing on study data for drug viewed as ‘oral Entyvio’
26 Apr 2023 //
BIOPHARMADIVE
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort
25 Apr 2023 //
GLOBENEWSWIRE
Morphic Announces Corporate Highlights andFYR for the 1Q 2023
25 Apr 2023 //
GLOBENEWSWIRE
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
24 Apr 2023 //
GLOBENEWSWIRE
Morphic to Present at TD Cowen 43rd Annual Health Care Conference
03 Mar 2023 //
GLOBENEWSWIRE
Morphic Announces Corporate Highlights and Financial Results for Full Year 2022
23 Feb 2023 //
GLOBENEWSWIRE
Morphic to Present at SVB Leerink Global Healthcare Conference
14 Feb 2023 //
GLOBENEWSWIRE
Morphic loses second partner as J&J exits integrin alliance
24 Jan 2023 //
PHARMA PHORUM
Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference
05 Jan 2023 //
GLOBENEWSWIRE
Morphic Therapeutic doses first subject in ulcerative colitis therapy trial
23 Nov 2022 //
CLINICALTRIALSARENA
Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057
22 Nov 2022 //
GLOBENEWSWIRE
Morphic Announces Financial Results for the Third Quarter 2022
02 Nov 2022 //
GLOBENEWSWIRE
Morphic Presents New Positive MORF-057 Phase 1 Data
25 Oct 2022 //
GLOBENEWSWIRE
Morphic Announces Complete Enrollment of EMERALD-1
24 Oct 2022 //
GLOBENEWSWIRE
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
10 Oct 2022 //
GLOBENEWSWIRE
Morphic Celebrates Foundational Integrin Research Published in Cell
21 Sep 2022 //
GLOBENEWSWIRE
Morphic Announces Participation in 2022 Wells Fargo Healthcare Conference
01 Sep 2022 //
GLOBENEWSWIRE
Morphic Announces Corporate Highlights and Financial Results for Q2 2022
03 Aug 2022 //
GLOBENEWSWIRE
AbbVie walks away from Morphic deal due to safety signal in preclinical testing
23 Jun 2022 //
ENDPTS
Morphic to Present at 2022 Jefferies Global Healthcare Conference
09 Jun 2022 //
GLOBENEWSWIRE
Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs
18 May 2022 //
GLOBENEWSWIRE
Morphic Names Bruce Rogers as President and Blaise Lippa as CSO
12 May 2022 //
GLOBENEWSWIRE
Morphic Therapeutic Expands Leadership with Key Appointments
06 Apr 2022 //
GLOBENEWSWIRE
Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel
30 Mar 2022 //
GLOBENEWSWIRE
Morphic Initiates EMERALD-1 Phase 2a Trial of MORF-057 in Ulcerative Colitis
25 Mar 2022 //
GLOBENEWSWIRE
Morphic Announces Participation In Cowen 42nd Annual Healthcare Conference
04 Mar 2022 //
GLOBENEWSWIRE
AbbVie ditches Morphic`s fibrosis program after `safety signal`
25 Feb 2022 //
FIERCEBIOTECH
Morphic Announces Corporate Highlights and Financial Results for Full Year 2021
24 Feb 2022 //
GLOBENEWSWIRE
Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022
22 Feb 2022 //
GLOBENEWSWIRE
Morphic Announces Corporate Highlights and Second Quarter 2021 Financial Results
04 Aug 2021 //
GLOBENEWSWIRE
Morphic announces positive results from phase 1 trial of MORF-057
12 Jul 2021 //
PHARMABIZ
Morphic announces positive results from phase 1 trial of MORF-057
12 Jul 2021 //
PHARMABIZ
Morphic announces positive results from phase 1 trial of MORF-057
12 Jul 2021 //
PHARMABIZ
